RU2017110093A - Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса - Google Patents
Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса Download PDFInfo
- Publication number
- RU2017110093A RU2017110093A RU2017110093A RU2017110093A RU2017110093A RU 2017110093 A RU2017110093 A RU 2017110093A RU 2017110093 A RU2017110093 A RU 2017110093A RU 2017110093 A RU2017110093 A RU 2017110093A RU 2017110093 A RU2017110093 A RU 2017110093A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- polypeptide
- amino acid
- acid sequence
- yaraaarqarakalarqlgvaa
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 43
- 230000001594 aberrant effect Effects 0.000 title claims 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims 5
- 238000009825 accumulation Methods 0.000 title claims 4
- 210000002744 extracellular matrix Anatomy 0.000 title claims 4
- 210000002950 fibroblast Anatomy 0.000 title claims 3
- 230000035755 proliferation Effects 0.000 title claims 3
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000008569 process Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 5
- 210000004072 lung Anatomy 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 3
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 208000036065 Airway Remodeling Diseases 0.000 claims 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 2
- 108091054455 MAP kinase family Proteins 0.000 claims 2
- 102000043136 MAP kinase family Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 208000027771 Obstructive airways disease Diseases 0.000 claims 1
- 208000037273 Pathologic Processes Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100036202 Serum amyloid P-component Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 244000309464 bull Species 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108091007231 endothelial receptors Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960001469 fluticasone furoate Drugs 0.000 claims 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000009054 pathological process Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 150000003815 prostacyclins Chemical class 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000004648 relaxation of smooth muscle Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/473,339 | 2014-08-29 | ||
| US14/473,339 US9890200B2 (en) | 2011-04-12 | 2014-08-29 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/047390 WO2016033432A1 (en) | 2014-08-29 | 2015-08-28 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017110093A3 RU2017110093A3 (enExample) | 2018-10-01 |
| RU2017110093A true RU2017110093A (ru) | 2018-10-01 |
Family
ID=52583553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017110093A RU2017110093A (ru) | 2014-08-29 | 2015-08-28 | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890200B2 (enExample) |
| EP (1) | EP3185883A4 (enExample) |
| JP (1) | JP2017528454A (enExample) |
| KR (1) | KR20170044171A (enExample) |
| CN (1) | CN107073075A (enExample) |
| AU (1) | AU2015308761A1 (enExample) |
| BR (1) | BR112017003731A2 (enExample) |
| CA (1) | CA2958085A1 (enExample) |
| MX (1) | MX2017002476A (enExample) |
| RU (1) | RU2017110093A (enExample) |
| SG (1) | SG11201701135WA (enExample) |
| WO (1) | WO2016033432A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| WO2016112292A1 (en) | 2015-01-08 | 2016-07-14 | Moerae Matrix, Inc. | Formulation of mk2 inhibitor peptides |
| JP2018512401A (ja) * | 2015-03-12 | 2018-05-17 | モイライ マトリックス インコーポレイテッド | Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 |
| CN112920256B (zh) * | 2019-11-21 | 2022-08-19 | 上海医药工业研究院 | 一种治疗哮喘的生物肽及其应用 |
| EP4464694A1 (en) | 2022-01-14 | 2024-11-20 | Shanghai Hansoh Biomedical Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| FR2585563B1 (fr) | 1985-07-30 | 1993-11-12 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| EP0672159B1 (en) | 1992-04-24 | 2005-12-28 | Sri International | Homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| WO1995015972A1 (en) | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| MX9603414A (es) * | 1994-02-17 | 1997-03-29 | American Home Prod | Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa. |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| WO2000059476A1 (en) | 1999-04-05 | 2000-10-12 | Pharmaceutical Discovery Corporation | Methods for fine powder formation |
| AU779986B2 (en) | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| KR20110017465A (ko) | 2002-04-25 | 2011-02-21 | 더 스크립스 리서치 인스티튜트 | 폐질환 증상의 치료 및 예방 |
| KR20130001318A (ko) | 2002-07-19 | 2013-01-03 | 애보트 바이오테크놀로지 리미티드 | ＴＮＦα 관련 질환의 치료 |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| EP1937219B1 (en) | 2005-09-14 | 2015-11-11 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| MX2008012794A (es) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Microparticulas de farmacos. |
| EP2155228B1 (en) | 2007-01-10 | 2014-04-02 | Purdue Research Foundation | Polypeptide inhibitors of hsp27 kinase and uses therefor |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| KR20170001756A (ko) | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| CN105920582B (zh) | 2008-12-10 | 2020-04-14 | 普渡研究基金会 | 基于细胞渗透性肽的激酶抑制剂 |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG10201604560TA (en) * | 2011-04-12 | 2016-07-28 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2014
- 2014-08-29 US US14/473,339 patent/US9890200B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 WO PCT/US2015/047390 patent/WO2016033432A1/en not_active Ceased
- 2015-08-28 JP JP2017511933A patent/JP2017528454A/ja active Pending
- 2015-08-28 MX MX2017002476A patent/MX2017002476A/es unknown
- 2015-08-28 BR BR112017003731A patent/BR112017003731A2/pt not_active IP Right Cessation
- 2015-08-28 AU AU2015308761A patent/AU2015308761A1/en not_active Abandoned
- 2015-08-28 EP EP15835631.1A patent/EP3185883A4/en not_active Withdrawn
- 2015-08-28 KR KR1020177007622A patent/KR20170044171A/ko not_active Withdrawn
- 2015-08-28 CN CN201580058532.3A patent/CN107073075A/zh active Pending
- 2015-08-28 RU RU2017110093A patent/RU2017110093A/ru not_active Application Discontinuation
- 2015-08-28 SG SG11201701135WA patent/SG11201701135WA/en unknown
- 2015-08-28 CA CA2958085A patent/CA2958085A1/en not_active Abandoned
-
2017
- 2017-12-27 US US15/855,398 patent/US10562947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20180194817A1 (en) | 2018-07-12 |
| SG11201701135WA (en) | 2017-03-30 |
| KR20170044171A (ko) | 2017-04-24 |
| US10562947B2 (en) | 2020-02-18 |
| JP2017528454A (ja) | 2017-09-28 |
| BR112017003731A2 (pt) | 2017-12-05 |
| RU2017110093A3 (enExample) | 2018-10-01 |
| EP3185883A1 (en) | 2017-07-05 |
| WO2016033432A9 (en) | 2016-04-21 |
| MX2017002476A (es) | 2017-08-14 |
| EP3185883A4 (en) | 2018-05-30 |
| CN107073075A (zh) | 2017-08-18 |
| AU2015308761A1 (en) | 2017-02-23 |
| CA2958085A1 (en) | 2016-03-03 |
| US20150064134A1 (en) | 2015-03-05 |
| US9890200B2 (en) | 2018-02-13 |
| WO2016033432A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| JP2014533235A5 (enExample) | ||
| JP2023099233A (ja) | 抗ｔｓｌｐ抗体による喘息治療 | |
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| US12503501B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | |
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| Wei-xu et al. | Therapeutic potential of anti-IL-1β IgY in guinea pigs with allergic asthma induced by ovalbumin | |
| JP2010539243A (ja) | 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤 | |
| Li et al. | CpG-ODNs and budesonide act synergistically to improve allergic responses in combined allergic rhinitis and asthma syndrome induced by chronic exposure to ovalbumin by modulating the TSLP-DC-OX40L axis | |
| RU2017121090A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| JP2018501201A5 (enExample) | ||
| CN103998053A (zh) | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 | |
| JP2017528454A5 (enExample) | ||
| Li et al. | Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization | |
| JP2017509633A5 (enExample) | ||
| BR112020017445A2 (pt) | anticorpos anti cd6 para tratar asma severa | |
| RU2016140332A (ru) | Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) | |
| US8653146B2 (en) | Method for treating Th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor | |
| Marzoog | Pulmonary fibrosis; risk factors and molecular triggers, insight for neo therapeutic approach | |
| JP2002515459A (ja) | 喘息および他のアレルギー性症状を治療するための方法およびｔｎｆ−ｒｉｉ（ｐ７５）アゴニストを含む組成物の使用 | |
| US20150225476A1 (en) | Method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway | |
| TW200900077A (en) | Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody | |
| CN118019545A (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| Mommsen et al. | Productive capacity of alveolar macrophages and pulmonary organ damage after femoral fracture and hemorrhage in IL-6 knockout mice | |
| Laurent et al. | TGF-beta antibodies: a novel treatment for pulmonary fibrosis? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20210323 |